Jamieson is pleased to announce that it has advised the management team of Theramex on the sale of the business from a consortium of Carlyle and PAI Partners to Cinven.
Headquartered in London, Theramex develops, in-licenses and commercialises treatments across four core areas of women’s health; menopause, osteoporosis, contraception and fertility. Through its team of more than 500 employees, the Company offers a diversified portfolio of established and recently launched brands to healthcare professionals and patients in more than 80 countries across Europe, Africa, Asia-Pacific and Latin America. Theramex is a trusted leader in women’s health, with a strong track record of delivering effective and innovative therapies to women who need them. To date, its treatments have reached more than six million women worldwide.
John Greenland, Matthew Mowat and Sophie Falk advised the management team through their sale and re-investment in the business, along with future equity arrangements.
